NRG-GI007: Phase 1 Study of OBP-301, An Oncolytic Virus, and Definitive Chemoradiation in Locally Advanced Esophageal Cancer.

purposeDefinitive chemoradiation (CRT) is standard for patients with medically inoperable esophageal cancer. OBP-301 is a modified adenovirus that adds a human telomerase reverse transcriptase gene promoter, replicating only in tumor cells to cause lysis. METHODS AND MATERIALS: In this phase 1 study, OBP-301 was added to carboplatin/paclitaxel and radiation therapy (RT) (50.4 Gy). Patients received intratumoral OBP-301 via endoscopy 3 days prior to and then at days 12 and 26 of RT. The primary endpoint was protocol-defined dose-limiting toxicity. Secondary endpoints included clinical complete response (cCR) rate, number alive and alive without progression at 1 year.

resultsFrom June 2020 to July 2024, 15 evaluable patients were enrolled. Fourteen patients (93%) received all planned OBP-301 injections and 50.4 Gy RT. No dose-limiting toxicities were observed. The most common treatment-related grade 3/4 toxicities were neutropenia (40%) and lymphopenia (33%). Two patients died prior to restaging: 1 patient developed grade 5 respiratory failure 6 weeks after CRT (suspected RT pneumonitis), whereas a second patient had unrecognized airway involvement at baseline, which led to a tracheoesophageal fistula during Week 3 of CRT. The cCR rate for patients undergoing restaging (n = 13) was 100% (95% CI, 77-100), and 87% (95% CI, 62-96) for all 15 patients. At 1 year, 9 (60%) out of 15 patients are still alive and 8 (53%) are alive without progression.

conclusionsOBP-301 administration before and during CRT is feasible and safe, resulting in a very promising cCR rate. A randomized study is being planned to further evaluate safety and efficacy.